Skip to main content

UMSOM Researchers Discover Certain Skin-Related Stem Cells Could Help in Treating Neurogenerative Diseases

May 06, 2019 | Joanne Morrison

Thomas J. Hornyak, MD, PhD

UMSOM Researchers Discovered that Pigment-Producing Stem Cells Can Help Regenerate Vital Part of Nervous System

Neurodegenerative diseases like multiple sclerosis (MS) affect millions of people worldwide and occur when parts of the nervous system lose function over time. Researchers at the University of Maryland School of Medicine (UMSOM) have discovered that a type of skin-related stem cell could be used to help regenerate myelin sheaths, a vital part of the nervous system linked to neurodegenerative disorders.

The discovery into these types of stem cells is significant because they could offer a simpler and less invasive alternative to using embryonic stem cells. This early stage research showed that by using these skin-related stem cells, researchers were able to restore myelin sheath formation in mice.

“This research enhances the possibility of identifying human skin stem cells that can be isolated, expanded, and used therapeutically. In the future, we plan to continue our research in this area by determining whether these cells can enhance functional recovery from neuronal injury,” said Thomas J. Hornyak, MD, PhD, Associate Professor and Chairman of the Department of Dermatology, and Principal Investigator in this research. “In the future, we plan to continue our research in this area by determining whether these cells can enhance functional recovery from neuronal injury.”

Using a mouse model, Dr. Hornyak’s team of researchers discovered a way to identify a specific version of a cell known as a melanocyte stem cell. These are the precursor cells to the cells in skin and hair follicles that make a pigment know as melanin, which determines the color of skin and hair. These melanocyte stem cells have the ability to continue to divide without limit, which is a trait that is not shared by other cells in the body. Additionally, the researchers discovered that these stem cells can make different types of cells depending on the type of signals they receive. This research was published in PLoS Genetics.

Importantly, unlike the embryonic stem cell, which must be harvested from an embryo, melanocyte stem cells can be harvested in a minimally-invasive manner from skin.

Isolating Skin Stem Cells for New Therapies

Dr. Hornyak’s research team found a new way to not only identify the right kind of melanocyte stem cells, but also the potential applications for those suffering from neurodegenerative disorders. By using a protein marker that is only found on these specialized cells, Dr. Hornyak’s research group was able to isolate this rare population of stem cells from the majority of the cells that make up skin. Additionally, they found that there exist two different types of melanocyte stem cells, which helped in determining the type of cells they could create.

Using this knowledge, the UMSOM researchers determined that under the right conditions, these melanocyte stem cells could function as cells that produce myelin, the major component of a structure known as the myelin sheath, which protects neurons and is vital to the function of our nervous system. Some neurodegenerative diseases, like multiple sclerosis, are caused by the loss of these myelin-producing, or glial, cells which ultimately lead to irregular function of the neurons and ultimately a failure of our nervous system to function correctly.

Growing Melanocyte Stem Cells

Dr. Hornyak and members of his laboratory grew melanocyte stem cells with neurons isolated from mice that could not make myelin. They discovered that these stem cells behaved like a glial cell under these conditions. These cells ultimately formed a myelin sheath around the neurons that resembled structures of a healthy nerve cell. When they took this experiment to a larger scale, in the actual mouse, the researchers found that mice treated with these melanocyte stem cells had myelin sheath structures in the brain as opposed to untreated mice who lacked these structures.

“This research holds promise for treating serious neurodegenerative diseases that impact millions of people each year. Our researchers at the University of Maryland School of Medicine have discovered what could be a critical and non-invasive way to use stem cells as a therapy for these diseases,” said UMSOM Dean, E. Albert Reece, MD, PhD, MBA, Executive Vice President for Medical Affairs, UM Baltimore, and the John Z. and Akiko K. Bowers Distinguished Professor.

Dr. Hornyak’s research was funded by the National Institute of Arthritis, Musculoskeletal, and Skin Diseases, National Institutes of Health, and the U.S. Department of Health & Human Services., the Biomedical Laboratory Research & Development Service, VA Office of Research Development, and U.S. Department of Veterans Affairs.

About the University of Maryland School of Medicine

Now in its third century, the University of Maryland School of Medicine was chartered in 1807 as the first public medical school in the United States. It continues today as one of the fastest growing, top-tier biomedical research enterprises in the world -- with 43 academic departments, centers, institutes, and programs; and a faculty of more than 3,000 physicians, scientists, and allied health professionals, including members of the National Academy of Medicine and the National Academy of Sciences, and a distinguished recipient of the Albert E. Lasker Award in Medical Research.  With an operating budget of more than $1 billion, the School of Medicine works closely in partnership with the University of Maryland Medical Center and Medical System to provide research-intensive, academic and clinically-based care for more than 1.2 million patients each year. The School of Medicine faculty, which ranks as the 8th highest among public medical schools in research productivity, is an innovator in translational medicine, with 600 active patents and 24 start-up companies. The School works locally, nationally, and globally, with research and treatment facilities in 36 countries around the world. Visit


Department of Anesthesiology
(410) 328-6120 (phone)
(410) 328-5531 (fax)

Joanne Morrison
Director of Marketing and Public Relations
Center for Vaccine Development and Global Health
University of Maryland School of Medicine
Office: (410) 706-2884
Mobile: (202) 841-3369

Related stories

    Tuesday, February 07, 2017

    University of Maryland School of Medicine Announces New Leadership Appointments in the Department of Dermatology to Bridge Research and Clinical Strengths

    University of Maryland School of Medicine (UM SOM) Dean E. Albert Reece, MD, PhD, MBA, announced today that Thomas J. Hornyak, MD, PhD, an Associate Professor of Dermatology at the School of Medicine, and internationally recognized physician-scientist in melanoma and skin cancer, has been named the new Chairman of the Department of Dermatology at UMSOM. He will also serve as Chief of Dermatology at the University of Maryland Medical Center (UMMC). In addition, Zaineb Makhzoumi, MD, MPH, an Assistant Professor of Dermatology at UM SOM, and skin cancer surgeon, has been named the Department’s Chief of Clinical Services.